Most cited papers from Nuvisan (Germany)

Nuvisan (Germany)

What are the most cited papers from Nuvisan (Germany)?

The most cited paper from Nuvisan (Germany) is "Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer" (Ezra E.W. Cohen et al., 2014), with 579 citations. Next come "Solution Conformations Shed Light on PROTAC Cell Permeability" (201) and "The Effect of Hematocrit on Bioanalysis of DBS: Results from The EBF DBS-Microsampling Consortium" (134).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 59 papers. Every paper with more than 15 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer Ezra E.W. Cohen et al. · Journal of Clinical Oncology Open access	22 Jul 2014	579
2	Solution Conformations Shed Light on PROTAC Cell Permeability Yoseph Atilaw, Vasanthanathan Poongavanam, Caroline Svensson Nilsson et al. · ACS Medicinal Chemistry Letters Open access	25 Dec 2020	201
3	The Effect of Hematocrit on Bioanalysis of DBS: Results from The EBF DBS-Microsampling Consortium Ronald de Vries, Matthew D. Barfield, Nico van de Merbel et al. · Bioanalysis	5 Jul 2013	134
4	Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist Victoria E R Parker, Darren C. Robertson, Tao Wang et al. · The Journal of Clinical Endocrinology & Metabolism Open access	14 Oct 2019	122
5	JUMP Cell Painting dataset: morphological impact of 136,000 chemical and genetic perturbations Srinivas Niranj Chandrasekaran et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access	24 Mar 2023	110
6	Minimized estradiol absorption with ultra-low-dose 10 μg 17β-estradiol vaginal tablets M. Eugster-Hausmann, Josef Waitzinger, Dirk Lehnick · Climacteric	28 Apr 2010	107
7	Nickel‐Catalyzed N ‐Arylation of NH ‐Sulfoximines with Aryl Halides via Paired Electrolysis Dong Liu, Zhao‐Ran Liu, Cong Ma et al. · Angewandte Chemie International Edition	12 Feb 2021	104
8	Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer Sebastian M. Dieter et al. · Cell Reports Open access	Jul 2021	94
9	Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase Colin W. Garvie et al. · Nature Communications Open access	16 Jul 2021	93
10	MISpheroID: a knowledgebase and transparency tool for minimum information in spheroid identity Arne Peirsman et al. · Nature Methods Open access	Nov 2021	87
11	Target 2035 – update on the quest for a probe for every protein Susanne Müller et al. · RSC Medicinal Chemistry Open access	3 Dec 2021	83
12	Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers Adam J. Davenport, Ioana Berindan‐Neagoe, Nico Bräuer et al. · Scientific Reports Open access	6 Oct 2021	69
13	Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042) Michael G. Hahn et al. · Journal of Medicinal Chemistry Open access	19 Apr 2021	67
14	First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis Lutz Renders, Klemens Budde, Christian Rosenberger et al. · PLoS ONE Open access	27 Mar 2019	64
15	In-Depth Study of Homogeneity in DBS Using Two Different Techniques: Results from The EBF DBS-Microsampling Consortium Zoe Cobb, Ronald de Vries, Neil Spooner et al. · Bioanalysis	5 Jul 2013	64
16	Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8 Andreas Port, Jamie V. Shaw, Lena Klopp‐Schulze et al. · Pharmacology Research & Perspectives Open access	19 Aug 2021	57
17	Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers Willi Cawello, Bernd Rosenkranz, Hans Bernhard Schmid et al. · Epilepsia	29 Jan 2013	57
18	Short-term variability of the human serum metabolome depending on nutritional and metabolic health status Inoncent Agueusop, Petra B. Musholt, BEATE M. KLAUS et al. · Scientific Reports Open access	Oct 2020	51
19	Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study Peter Joseph Jongen, Dirk Lehnick, Evert A. C. M. Sanders et al. · Health and Quality of Life Outcomes Open access	2010	50
20	Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses Simon R. Heller, Sarah Glaeske, Katja Gluske et al. · Clinical and Experimental Medicine Open access	8 Nov 2023	45
21	The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models Clara Lemos, Volker Schulze, Simon J. Baumgart et al. · Cellular Oncology Open access	25 Jan 2021	45
22	Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women Barbara Schütt, Andreas Kaiser, Marcus‐Hillert Schultze‐Mosgau et al. · Human Reproduction	10 Jun 2016	45
23	Recommendations on The Interpretation of The New European Medicines Agency Guideline on Bioanalytical Method Validation By Global Cro Council For Bioanalysis (Gcc) Mark Boterman et al. · Bioanalysis	Mar 2012	45
24	Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy Bartlomiej Borek et al. · Molecular Cancer Therapeutics Open access	17 Mar 2023	38
25	Recommendations on Bioanalytical Method Stability Implications of Co-Administered And Co-Formulated Drugs By Global Cro Council For Bioanalysis (Gcc) Steve Lowes et al. · Bioanalysis	Sep 2012	33
26	Toward understanding lipid reorganization in RNA lipid nanoparticles in acidic environments Adiran Garaizar, Christian David Díaz‐Oviedo, Nina Zablowsky et al. · Proceedings of the National Academy of Sciences Open access	30 Oct 2024	32
27	Targeting RAS oncogenesis with SOS1 inhibitors Roman Christian Hillig, Benjamin Bader · Advances in cancer research Book chapter	2022	32
28	Ocular metabolism and distribution of drugs in the rabbit eye: Quantitative assessment after intracameral and intravitreal administrations Eva Maria del Amo, Anam Hammid, Melanie Tausch et al. · International Journal of Pharmaceutics Open access	9 Dec 2021	32
29	No Clinically Relevant Interactions of St. John's Wort Extract Ze 117 Low in Hyperforin With Cytochrome P450 Enzymes and P‐glycoprotein Catherine Zahner, Esther Kruttschnitt, Julia Uricher et al. · Clinical Pharmacology & Therapeutics Open access	10 Feb 2019	30
30	CACHE Challenge #1: Targeting the WDR Domain of LRRK2, A Parkinson’s Disease Associated Protein Fengling Li et al. · Journal of Chemical Information and Modeling Open access	5 Nov 2024	29
31	BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models Ulrike Rauh et al. · Nature Cancer Open access	23 Aug 2024	29
32	Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21 Fabian Göricke et al. · Journal of Medicinal Chemistry Open access	20 Feb 2023	28
33	Identification of a neural development gene expression signature in colon cancer stem cells reveals a role for EGR2 in tumorigenesis Joseph L. Regan, Dirk Schumacher, Stephanie Staudte et al. · iScience Open access	31 May 2022	28
34	Artificial Intelligence in Toxicologic Pathology: Quantitative Evaluation of Compound-Induced Hepatocellular Hypertrophy in Rats Hannah Pischon, David Y. Mason, Bettina Lawrenz et al. · Toxicologic Pathology	5 Jan 2021	26
35	Incurred Sample Reproducibility: 10 Years of Experiences: Views and Recommendations from the European Bioanalysis Forum Morten Anders Kall, Marco Michi, Barry van der Strate et al. · Bioanalysis Open access	Nov 2018	25
36	Re-thinking the current paradigm for clinical immunogenicity assessment: an update from the discussion in the European Bioanalysis Forum Joanne Goodman et al. · Bioanalysis	9 Aug 2024	24
37	Conference Report: 4Th Global Cro Council For Bioanalysis: Coadministered Drugs Stability, Ema/Us Fda Guidelines, 483S And Carryover Steve Lowes et al. · Bioanalysis	Apr 2012	24
38	Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study The FOCUS Extension Study Group, Peter Joseph Jongen, Dirk Lehnick et al. · Journal of Neurology Open access	2 May 2014	24
39	Dual targeting of the androgen receptor and PI3K / AKT / mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis Tatsuo Sugawara, Ekaterina Nevedomskaya, Simon R. Heller et al. · Molecular Oncology Open access	15 Jan 2024	23
40	Targeting fatty acid oxidation via Acyl-CoA binding protein hinders glioblastoma invasion Ceren Duman, Barbara Di Marco, Ekaterina Nevedomskaya et al. · Cell Death and Disease Open access	29 Apr 2023	23
41	A Small Molecule–Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an αVß3 Binder for the Treatment of Multiple Cancer Types Hans‐Georg Lerchen, Beatrix Stelte‐Ludwig, Charlotte Kopitz et al. · Cancers Open access	13 Jan 2022	23
42	Update to the European Bioanalysis Forum Recommendation on Biomarkers Assays; Bringing Context of Use Into Practice Joanne Goodman, Kyra J. Cowan, Michaela Golob et al. · Bioanalysis	Oct 2020	23
43	Comparison of the Pharmacokinetic and Pharmacodynamic Profiles of One US-Marketed and Two European-Marketed Epoetin Alfas Michael Lissy, Marité Ode, Karsten Roth · Drugs in R&D Open access	Mar 2011	22
44	Development and validation of automated SPE‐HPLC‐MS/MS methods for the quantification of asenapine, a new antipsychotic agent, and its two major metabolites in human urine Theo de Boer, Erik Meulman, Henri Meijering et al. · Biomedical Chromatography	16 Feb 2012	22
45	Target 2035 – an update on private sector contributions Suzanne Z. Ackloo et al. · RSC Medicinal Chemistry Open access	2023	21
46	Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer Franziska Siegel et al. · Cancer Discovery Open access	15 Oct 2025	20
47	Absolute Bioavailability and Effect of Food on the Disposition of Safinamide Immediate Release Tablets in Healthy Adult Subjects Annick Seithel‐Keuth, Andreas Johne, Achim Freisleben et al. · Clinical Pharmacology in Drug Development	2013	20
48	Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists BAY-4931 and BAY-0069 Douglas L. Orsi, Elisabeth Pook, Nico Bräuer et al. · Journal of Medicinal Chemistry Open access	21 Oct 2022	19
49	DNA repair inhibitors sensitize cells differently to high and low LET radiation Kristina Bannik, Balázs Gergely Madas, Sabrina Jarke et al. · Scientific Reports Open access	Dec 2021	19
50	New Generation of sGC Stimulators: Discovery of Imidazo[1,2-a]pyridine Carboxamide BAY 1165747 (BAY-747), a Long-Acting Soluble Guanylate Cyclase Stimulator for the Treatment of Resistant Hypertension Alexandros Vakalopoulos et al. · Journal of Medicinal Chemistry	11 Apr 2023	18

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.